NCT02036580 - D2212C00002 J-Phase II Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

BIOLOGICAL

tralokinumab cohort 1

Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor

BIOLOGICAL

tralokinumab cohort 2

Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor

OTHER

Placebo

Trial Locations (5)

Unknown

Research Site, Fukuoka

Research Site, Himeji-shi

Research Site, Seto-shi

Research Site, Shibuya-ku

Research Site, Yokohama